The current standard-of-care is based on the KEYNOTE-811 study, which established the combination of pembrolizumab with trastuzumab and a fluoropyrimidine/platinum doublet. The approval is irrespective of PD-L1 status; about 85% of tumors in KEYNOTE--811 had PD-L1 CPS of 1 or more and we do await a ...

I agree with Dr. @Geoffrey Y. Ku and would add the following comments. First, it would be important to understand the reason the patient cannot tolerate any platinum as we recently saw data from the phase III GO2 trial suggesting reduced dosing of 5FU/platinum was safe and non-inferior in an older a...